JPMorgan Chase & Co. Grows Holdings in Imperva Inc (IMPV)

JPMorgan Chase & Co. lifted its holdings in Imperva Inc (NASDAQ:IMPV) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 208,863 shares of the software maker’s stock after acquiring an additional 9,398 shares during the period. JPMorgan Chase & Co.’s holdings in Imperva were worth $9,702,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP purchased a new stake in shares of Imperva during the third quarter worth about $4,914,000. Panagora Asset Management Inc. increased its stake in shares of Imperva by 16.6% during the third quarter. Panagora Asset Management Inc. now owns 248,107 shares of the software maker’s stock worth $11,525,000 after purchasing an additional 35,373 shares in the last quarter. Pictet Asset Management Ltd. increased its stake in shares of Imperva by 10.0% during the third quarter. Pictet Asset Management Ltd. now owns 681,419 shares of the software maker’s stock worth $31,652,000 after purchasing an additional 61,750 shares in the last quarter. Credit Suisse AG increased its stake in shares of Imperva by 17.7% during the third quarter. Credit Suisse AG now owns 479,824 shares of the software maker’s stock worth $22,288,000 after purchasing an additional 72,014 shares in the last quarter. Finally, Broadview Advisors LLC increased its stake in shares of Imperva by 2.4% during the third quarter. Broadview Advisors LLC now owns 290,725 shares of the software maker’s stock worth $13,504,000 after purchasing an additional 6,750 shares in the last quarter. 93.43% of the stock is owned by hedge funds and other institutional investors.

IMPV has been the subject of a number of research reports. BidaskClub raised shares of Imperva from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 16th. Zacks Investment Research cut shares of Imperva from a “buy” rating to a “hold” rating in a research note on Wednesday, December 12th. Finally, Royal Bank of Canada cut shares of Imperva from an “outperform” rating to a “sector perform” rating and set a $56.00 target price for the company. in a research note on Tuesday, November 6th. Ten equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $56.89.

Shares of NASDAQ IMPV opened at $55.74 on Monday. Imperva Inc has a 12-month low of $41.00 and a 12-month high of $57.65. The stock has a market cap of $1.98 billion, a P/E ratio of -199.07 and a beta of 1.09.

COPYRIGHT VIOLATION NOTICE: “JPMorgan Chase & Co. Grows Holdings in Imperva Inc (IMPV)” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.chaffeybreeze.com/2019/02/18/jpmorgan-chase-co-grows-holdings-in-imperva-inc-impv.html.

About Imperva

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Read More: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding IMPV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperva Inc (NASDAQ:IMPV).

Institutional Ownership by Quarter for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply